Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

Note payable - 75,000

Deferred product revenue - 189,000

Total current liabilities 7,273,296 17,255,849

Warrant liability 2,100,000 -

Deferred contract revenue 11,625,000 11,625,000

Deferred rent and credit on lease

concession 1,177,840 1,252,900

Total liabilities 22,176,136 30,133,749

Noncontrolling interest 7,337,811 -

Commitments and contingencies

Stockholders' equity (deficit):

Preferred stock, undesignated - -

Common stock, par value 467,488 363,625

Capital in excess of par value 189,019,188 164,593,930

Accumulated deficit (195,334,828) (153,085,462)

Accumulated other comprehensive loss - (73)

Total stockholders' equity (deficit) (5,848,152) 11,872,020

Total liabilities and

stockholders' equity (deficit) $23,665,795 $42,005,769

MIDDLEBROOK PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Year Ended December 31,

2007 2006

Cash flows from operating activities:

Net loss $(42,249,366) $(41,990,154)

Adjustments to reconcile net income

to net cash used in operating

activities:

Loss attributable to non-

controlling interest (162,189)
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 ...ch is set to take place on February 22-24, 2010 in...ay conference we will highlight key issues in form...hare their experiences. , ...genda for Arrowhead’s 2010 Personalized Med...
(Date:11/5/2009)...ON, Colo., Nov. 5 The endangered b...he western U.S. This rare carnivore feeds on prai...to plague and often entire population die-offs in ... (FWS) has implemented a ferret breeding program a...o their formerly native habitat. Unfortunately, p...
(Date:11/5/2009)...ORDOVA, Calif., Nov. 5 T...plier of innovative products for processing and st... the first quarter of fiscal 2010. ,, For the q...ted revenues of $5.2 million, a 15 percent increas...er a year ago. The Company said the key contributo...
(Date:11/5/2009)..., N.Y., Nov. 5 BioSpecif...maceutical company developing first-in-class colla...al results for the third quarter ended September 3...September of this year, the FDA,s Arthritis Adviso... 12-0, the approval of XIAFLEX(TM) for the treatme...
Breaking Biology Technology:Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5
... 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICAL...y that it has filed a New Drug Application (NDA) w...r its lead oncology therapeutic Onrigin (laromusti...ction treatment for patients sixty years of age or...emia (AML). The Company has requested a priority ...
.... 17 GeneGo, Inc., the leading systems biology to...censed 250 manually curated pathway maps from Gene...way Tool. Available at www.millipore.com/pathways...ies, proteins, and assays as well as relevant bioi... These maps have been categorized by diseases and ...
...y, February 17 , - Sales Grow by 10.7% to EUR1.... 36.6% From EUR1.34 Euro to, EUR1.83, - Ad...- CEO Dr. Axel Herberg: "Following the record year... well equipped to meet the global challenges in, ...es growth of 6% to 7% in, the core business."...
Other Biology Technology:Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 2Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 3Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 4Millipore Launches an Interactive Biological Pathway Tool Using GeneGo's Manually Curated Pathway Maps 2Millipore Launches an Interactive Biological Pathway Tool Using GeneGo's Manually Curated Pathway Maps 3Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009 2Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009 3Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009 4
(Date:11/4/2009)...in the cities of Long Beach and Riverside are resp...e childhood asthma, and the true impact of air pol...y been underestimated, according to researchers at... The study, which appears in an online edition of ... that nine percent of all childhood asthma cases i...
(Date:11/4/2009)...cteria, it turns out, hold the power to help milit...e world clean up toxic waste on test sites. , Co...e invented back in World War II and have been used...ergy compounds are often used to propel tank shell..., But with increased knowledge of their environme...
(Date:11/4/2009)...ma at Norman has received more than $10 million in...t of the federal stimulus program, bringing thetot...rchers to $23 million. Thirty-three projects achi...haeology to weather. , "The university has thoug...ng areasof scholarly excellence to federal agency ...
Breaking Biology News(10 mins):USC study finds big air pollution impacts on local communities 2Genomic research will enable greener cleanup of military explosive test sites 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Reportlinker Adds Nanoporous Materials Report 13904 1Reportlinker Adds Nanoporous Materials Report 13904 2Reportlinker Adds Nanoporous Materials Report 13904 3Reportlinker Adds Nanoporous Materials Report 13904 4Reportlinker Adds Nanoporous Materials Report 13904 5Reportlinker Adds Nanoporous Materials Report 13904 6Delta Health an InfoLogix Company Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 56400 1Delta Health an InfoLogix Company Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 56400 2Delta Health an InfoLogix Company Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 56400 3Vaxart Awarded NIH Grant to Support Development of Orally Delivered H5N1 Avian Influenza Vaccine 56397 1Vaxart Awarded NIH Grant to Support Development of Orally Delivered H5N1 Avian Influenza Vaccine 56397 2
..., Tobacco smokers who eat three servings of fruit...tea may be protecting themselves from lung cancer,...ncer researchers. , UCLA researchers found that ...als called flavonoids in their diet had a lower ri... since more than 90 percent of lung cancers are ca...
..., WEST LAFAYETTE, Ind. - Throughout the overlooke... small but important animal is rapidly disappearin...nergy-dense creature called Diporeia - was a major...ke lake whitefish and many prey fish upon which sa...ploying new research methods in a quest to explain...
..., AMES, Iowa -- An Iowa State University research...ir energy to producing healthier offspring. , Lis...gy, evolution and organismal biology, studied the ...ce and found that females that had been infected w...thy females. , This finding was unexpected becaus...
Other Biology News:Fruits, vegetables and teas may protect smokers from lung cancer, UCLA researchers report 2A Great Lakes mystery: The case of the disappearing species 2A Great Lakes mystery: The case of the disappearing species 3A Great Lakes mystery: The case of the disappearing species 4Mice mothers devote energies to offspring when life is threatened 2
Expansion and Cryopreservation of Cells from Meridian Life Science, Inc.
HandyStep manual repeating pipette from BrandTech Scientific
Zymo-Spin I-96 from Zymo Research
RT-PCR Grade Water from Ambion
Biology Products: